ライフサイエンスコーパス: voriconazole

1 ment groups (P < .001 for all comparisons vs voriconazole).

2 viation) of 75 (54) days after initiation of voriconazole.

3 among patients with periostitis who received voriconazole.

4 es are not commonly reported side effects of voriconazole.

5 concluded that they could not recommend oral voriconazole.

6 petitively inhibited by posaconazole but not voriconazole.

7 ntually, all patients were treated with oral voriconazole.

8 improved 3-month visual acuity compared with voriconazole.

9 ll 5 patients receiving primary therapy with voriconazole.

10 ely observed in patients receiving long-term voriconazole.

11 mal levels in hematologic patients receiving voriconazole.

12 a CrCl <50 mL/min and were treated with oral voriconazole.

13 atus isolates with reduced susceptibility to voriconazole.

14 results was 99.6% for both posaconazole and voriconazole.

15 inical breakpoints for both posaconazole and voriconazole.

16 azole was highly predictive of resistance to voriconazole.

17 lus spp. and itraconazole, posaconazole, and voriconazole.

18 a, C. lambica, and C. ciferrii remained S to voriconazole.

19 recipients given prophylactic fluconazole or voriconazole.

20 e than 8 months after the discontinuation of voriconazole.

21 d by the methylation of the antifungal agent voriconazole.

22 ns and long-term antifungal prophylaxis with voriconazole.

23 drug-drug interactions than those noted with voriconazole.

24 of isavuconazole was noninferior to that of voriconazole.

25 69) and amphotericin (0.70) and moderate for voriconazole (0.60), and the Pearson correlation of MICs

26 y MIC50 and MIC90 values were determined for voriconazole (1 and 2 mug/ml, respectively), itraconazol

27 al was designed to randomize 368 patients to voriconazole (1%) or natamycin (5%), applied topically e

28 mL), fluconazole (36.9 +/- 30.7 mug/mL), and voriconazole (1.9 +/- 2.9 mug/mL) are reported.

29 azole, 1 (98.8%); posaconazole, 0.5 (99.2%); voriconazole, 1 (97.7%); A. flavus, itraconazole, 1 (99.

30 nazole, 1 (99.6%); posaconazole, 0.25 (95%); voriconazole, 1 (98.1%); A. nidulans, itraconazole, 1 (9

31 nazole, 1 (100%); posaconazole, 0.5 (99.7%); voriconazole, 1 (99.1%); A. versicolor, itraconazole, 2

32 a placebo (all participants received topical voriconazole, 1%).

33 All patients received topical voriconazole, 1%, and after the results of the Mycotic U

34 All participants received topical voriconazole, 1%, and natamycin, 5%.

35 rticipants were randomly assigned to topical voriconazole, 1%, or topical natamycin, 5%.

36 0.02%, hexamidine diisethioonate, 0.1%, and voriconazole, 1.0%, were effective in completely killing

37 ody weight orally [p.o.] twice a day [BID]), voriconazole (10 mg/kg p.o. BID), liposomal amphotericin

38 convulsant thioperamide (1.65 A), antifungal voriconazole (2.35 A), and antifungal clotrimazole (2.50

39 2 (100%); posaconazole, 1 (not applicable); voriconazole, 2 (97.5%).

40 aconazole, 1 (95%); posaconazole, 1 (97.7%); voriconazole, 2 (99.3%); A. niger, itraconazole, 2 (100%

41 nazole, 2 (100%); posaconazole, 0.5 (96.9%); voriconazole, 2 (99.4%); A. terreus, itraconazole, 1 (10

42 1 to 21 mm), posaconazole (28 to 35 mm), and voriconazole (25 to 33 mm); and C. krusei, amphotericin

43 as determined for fluconazole (21 isolates), voriconazole (28 isolates), amphotericin (29 isolates),

44 8 to 26 mm), posaconazole (28 to 38 mm), and voriconazole (29 to 39 mm).

45 e daily); and group 4, AmB (0.7-1 mg/kg) and voriconazole (300 mg twice daily).

46 amphotericin B, 430 mg daily, but changed to voriconazole, 300 mg twice daily, secondary to renal ins

47 erapy (n = 20) or intrastromal injections of voriconazole 50 mug/0.1 ml (n = 20).

48 ith isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment d

49 able 12-week response rate was obtained with voriconazole (54.7%) than with AmB (29.9%) (P < .0001).

50 ither intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1

51 d a CrCl <50 mL/min and received intravenous voriconazole, 77 (46.4%) had a CrCl >/=50 mL/min and rec

52 apy of fluconazole (60%), caspofungin (24%), voriconazole (8%), or liposomal amphotericin B (5%).

53 mphigus vulgaris responded to treatment with voriconazole, 8 mg/kg/d, for 24 days.

54 f 1.8-line improvement with natamycin versus voriconazole (95% confidence interval 0.5-3.0, P = 0.006

55 ,619 isolates of Candida spp. tested against voriconazole, 95.0% were S and 3% were R.

56 In contrast, voriconazole, a CYP46A1 inhibitor, was severely toxic ev

57 C results obtained for both posaconazole and voriconazole after only 24 h of incubation may be used t

58 gainst 46 (51%) of the 91 isolates, and with voriconazole against 48 (53%) of the 91 isolates.

59 micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resist

60 values for isavuconazole, posaconazole, and voriconazole against Candida spp. were 0.5, 1, and 0.25

61 48-h MIC determinations of posaconazole and voriconazole against more than 16,000 clinical isolates

62 The pharmacodynamics of voriconazole against wild-type and 3 resistant strains o

63 In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% conf

64 Eyes treated with oral voriconazole also had a mean 0.29 decreased logMAR (impr

65 ve role under glaucomatous conditions, while voriconazole, an antifungal drug, is retinotoxic.

66 Nineteen patients receiving topical voriconazole and 16 patients who were given intrastromal

67 ine patients started treatment (32 receiving voriconazole and 27 receiving placebo) and were included

68 Of these, 33 (45.8%) were randomized to oral voriconazole and 39 (54.2%) to placebo.

69 Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptibl

70 ity of </= 1 mug/ml has been established for voriconazole and all species of Candida, it is notable t

71 IA were randomly assigned to treatment with voriconazole and anidulafungin or placebo.

72 ium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the hig

73 pediatric patients treated with combination voriconazole and caspofungin (V/C) salvage therapy for r

74 in the pediatric population with concurrent voriconazole and caspofungin therapy.

75 rystal structures of CYP46A1 in complex with voriconazole and clotrimazole, and in the present work w

76 x with other drugs, including the antifungal voriconazole and clotrimazole.

77 le, fluconazole, itraconazole, ketoconazole, voriconazole and ketaminazole bound tightly to CYP51 (Kd

78 ntrast, fluconazole did not bind to CYP5218, voriconazole and ketaminazole bound weakly (Kd ~107 and

79 Minimum inhibitory concentration of voriconazole and natamycin in baseline cultures.

80 nfidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3

81 n analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependen

82 was no association between susceptibility to voriconazole and outcome.

83 Between the voriconazole and placebo groups, there were no significa

84 Voriconazole and posaconazole MICs were 0.5-4 and 0.06-0

85 rm the ability of the Etest method to detect voriconazole and posaconazole resistance among Aspergill

86 in vitro showed mostly high MICs, except for voriconazole and the echinocandins.

87 ition, and x-ray structure in complexes with voriconazole and the experimental inhibitor (R)-N-(1-(2,

88 r triazoles (itraconazole, posaconazole, and voriconazole) and common Aspergillus species.

89 .1 to 5.7% for posaconazole, 0.0 to 1.6% for voriconazole, and 0.7 to 4.0% for itraconazole.

90 Fifteen continued to receive voriconazole, and 10 were switched to amphotericin B.

91 a CrCl >/=50 mL/min and received intravenous voriconazole, and 47 (28.3%) had a CrCl <50 mL/min and w

92 2 and May 2013 for agreement of fluconazole, voriconazole, and amphotericin B susceptibility results

93 cin compared with those randomly assigned to voriconazole, and especially among patients with Fusariu

94 tericin B, intravitreal amphotericin B, oral voriconazole, and intravitreal voriconazole occurred in

95 The species has a higher amphotericin B, voriconazole, and itraconazole MIC and causes more chron

96 clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have been revised to

97 le, itraconazole, fluconazole, posaconazole, voriconazole, and the three echinocandins were assessed

98 BSI isolates of C. glabrata to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin

99 or susceptibility were used for fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin

100 amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, an

101 Susceptibility to voriconazole appeared to decrease during the relatively

102 ogenous fungal endophthalmitis, intravitreal voriconazole appears to provide the broadest spectrum of

103 Potential CLSI breakpoints for voriconazole are </= 0.5 mg/L for susceptible and >1 mg/

104 Potential EUCAST breakpoints for voriconazole are </=1 mg/L for susceptible and >2 mg/L f

105 aconazole), 98.4% (posaconazole), and 99.6% (voriconazole) assessing EA at +/-2 dilutions and 99.6% (

106 ole, reflecting either selective pressure or voriconazole-associated alterations in Zygomycetes virul

107 the current data and potential mechanisms of voriconazole-associated photosensitivity and carcinogene

108 ize the natural history of these potentially voriconazole-associated tumors, a nationwide call for no

109 of Optisol-GS were supplemented with either voriconazole at 1x, 10x, 25x, or 50x minimum inhibitory

110 aconazole), 87.7% (posaconazole), and 96.3% (voriconazole) at +/-1 dilution.

111 rns or young infants, as the under-dosage of voriconazole based on adult data revealed.

112 ause mortality, whereas the initial use of a voriconazole-based regimen showed a protective effect (H

113 Glucose has a higher affinity to bind with voriconazole by hydrogen bonding and decrease the suscep

114 Three Zygomycetes strains were exposed to voriconazole by serial passages on voriconazole-containi

115 methods for itraconazole, posaconazole, and voriconazole by testing 245 Aspergillus clinical isolate

116 triazole antifungal agents, itraconazole and voriconazole, causing neuropathy.

117 od volume variation and also to quantify the voriconazole concentration for 26 patients undergoing vo

118 netic resonance imaging (MRI), serum and CSF voriconazole concentrations, and clinician assessment of

119 xposed to voriconazole by serial passages on voriconazole-containing medium.

120 site with tranylcypromine, thioperamide, and voriconazole coordinating the heme iron via their nitrog

121 Voriconazole could be a good choice for treating corneal

122 The addition of caspofungin and voriconazole decreased growth of Candida in a species-de

123 MUTT II showed that oral voriconazole did not improve outcomes overall, although

124 001), alkaline phosphatase (P = .020), daily voriconazole dose (P < .001), and cumulative voriconazol

125 voriconazole dose (P < .001), and cumulative voriconazole dose (P = .027) were significantly elevated

126 tive infections repeatedly required profound voriconazole dose reductions whenever high-dose meropene

127 Moreover, treatment with voriconazole due to the Aspergillus flavus and meropenem

128 d best in testing amphotericin B (EA, 100%), voriconazole (EA, 93.7%), and posaconazole (EA, 94.8%) a

129 Patients receiving oral voriconazole experienced a total of 58 adverse events (4

130 The virulence of voriconazole-exposed Zygomycetes strains was compared wi

131 Voriconazole exposure decreased mortality in 2002-2011 (

132 ports describing skin cancer associated with voriconazole exposure emerged shortly after US Food and

133 ungal therapy (24.1% vs 30.2%, P = .11) with voriconazole, FFS rates (75% vs 78%; P = .49) at 180 day

134 atients treated with the same formulation of voriconazole for a minimum of 3 consecutive days were in

135 ) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species

136 Patients who received voriconazole for at least 1 month for probable or confir

137 Of 114 patients who were off voriconazole for at least 3 months, hair loss had stoppe

138 center trial comparing topical natamycin and voriconazole for fungal keratitis treatment.

139 a benefit of topical natamycin over topical voriconazole for fungal ulcers, particularly among those

140 Survival was higher for voriconazole for mycologically documented (probable/prov

141 Isavuconazole was non-inferior to voriconazole for the primary treatment of suspected inva

142 of monotherapy with topical natamycin versus voriconazole for the treatment of fungal keratitis.

143 linical trial comparing topical natamycin or voriconazole for treating filamentous fungal keratitis.

144 e collected for 197,619 isolates tested with voriconazole from 2001 to 2007.

145 .6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabra

146 ment was significantly better in the topical voriconazole group (P = 0.008).

147 Fusarium ulcers randomized to oral voriconazole had a 0.43-fold decreased hazard of perfora

148 about reversal of hair loss were asked after voriconazole had been stopped for at least 3 months.

149 neral, of the eight antifungal drugs tested, voriconazole had the greatest in vitro activity, while a

150 eiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0

151 tested, we demonstrate that tioconazole and voriconazole have the greatest overall inhibition for al

152 and 16 patients who were given intrastromal voriconazole healed with therapy.

153 he emergence and geographical migration of a voriconazole highly resistant A. fumigatus that was asso

154 ght to determine whether a 3-month course of voriconazole improved asthma-related outcomes in patient

155 efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease.

156 eficial effect of 3 months of treatment with voriconazole in patients with moderate-to-severe asthma

157 he current data regarding the implication of voriconazole in the development of skin cancer in organ

158 physicians should consider prescribing oral voriconazole in these cases.

159 The mechanism of voriconazole-induced skin cancer is still unknown and ma

160 Through GCMS, we demonstrate that voriconazole inhibits 14alpha-demethylase as treatment i

161 iconazole involvement, the mean time between voriconazole initiation and SCC diagnosis was 39 +/- 18

162 A multidisciplinary committee evaluated voriconazole involvement in each case.

163 The committee determined the likelihood of voriconazole involvement to be high in 15 cases, interme

164 atients with high/intermediate likelihood of voriconazole involvement, the mean time between voricona

165 Voriconazole is a first-line agent for the treatment of

166 Voriconazole is a triazole antifungal medication used fo

167 Voriconazole is a widely prescribed antifungal medicatio

168 AmB plus voriconazole is an effective alternative combination in

169 of the drug, and it is now established that voriconazole is an independent risk factor for the devel

170 The cytochrome P450 51 (CYP51) inhibitor voriconazole is currently the drug of choice, yet the tr

171 tion should be sought, as discontinuation of voriconazole is effective at reversing the disease.

172 determined susceptibilities to fluconazole, voriconazole, itraconazole, posaconazole, amphotericin B

173 ugs that are used systemically (fluconazole, voriconazole, ketoconazole, itraconazole, and posaconazo

174 Serum voriconazole levels varied, and CSF concentrations of vo

175 receive oral voriconazole vs oral placebo; a voriconazole loading dose of 400 mg was administered twi

176 Voriconazole long-term therapy is suspected to induce cu

177 ill incidence rate, 40% [6 of 15 isolates]), voriconazole (median growth grade, 2.0; kill incidence r

178 entration was elevated in patients receiving voriconazole (median, 156.5 mug/L; interquartile range,

179 30 muM 24(S)-HC was required to prevent the voriconazole-mediated retinal damage.

180 Among voriconazole-treated cases, the voriconazole MIC did not correlate with any of the measu

181 azole, of which 98.8% were nonsusceptible to voriconazole (MIC > 0.5 mug/ml) and 9.3%, 9.3%, and 8.0%

182 similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fol

183 ase per year (95% CI, 1.13-4.56; P = .02) in voriconazole MICs after controlling for the infectious o

184 le MICs were >2 mug/ml, the posaconazole and voriconazole MICs were greater than the ECVs for 14 and

185 121F/T289A isolates were highly resistant to voriconazole (minimum inhibitory concentration >/=16 mg/

186 Compared with voriconazole monotherapy, combination therapy with anidu

187 nown and may involve its primary metabolite, voriconazole N-oxide.

188 atients with hematologic malignancies taking voriconazole (n = 20), posaconazole (n = 8), and itracon

189 trial compared fluconazole (N = 295) versus voriconazole (N = 305) for the prevention of IFI in the

190 ygomycetes strains was compared with that of voriconazole-nonexposed strains in Drosophila and murine

191 ricin B, oral voriconazole, and intravitreal voriconazole occurred in 34.8%-43.5%, 0-8.3%, 68.8%, 69.

192 To explore the role of adjuvant oral voriconazole on clinical outcomes in Fusarium keratitis.

193 or worse and were randomized to receive oral voriconazole or a placebo (all participants received top

194 possible IA in patients treated with either voriconazole or AmB.

195 01), fluconazole use within 30 days prior to voriconazole (OR, 6.21; P = .008), coadministration of p

196 m; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone.

197 ne; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromyci

198 pisodes and confirmed the higher efficacy of voriconazole over AmB deoxycholate in mycologically docu

199 eiving isavuconazole and 155 (60%) receiving voriconazole (p<0.001).

200 eloped that enabled simulation of human-like voriconazole pharmacokinetics.

201 azole, or amphotericin; newer triazoles (ie, voriconazole, posaconazole) have been demonstrated to be

202 ive concentrations (MECs) of amphotericin B, voriconazole, posaconazole, caspofungin, and micafungin

203 ifungal agents (amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, anidulafungin,

204 Our results suggest that long-term voriconazole prescription may be associated with a multi

205 heoretical docking studies demonstrated that voriconazole presented three important hydrogen bonds an

206 eveloped invasive fungal infections while on voriconazole prophylaxis and three developed fungal infe

207 ons (IMIs) that occur during posaconazole or voriconazole prophylaxis are rare complications for whic

208 treatment with vancomycin, levofloxacin, and voriconazole prophylaxis resulted in no further infectio

209 Despite secondary voriconazole prophylaxis, fungal infections developed in

210 tuzumab induction therapy and posttransplant voriconazole prophylaxis.

211 The complex with voriconazole provides an explanation for the potency of

212 risk for fungal infection who are receiving voriconazole, reflecting either selective pressure or vo

213 cases fared better with natamycin than with voriconazole (regression coefficient=0.41 logMAR; 95% CI

214 exes with tranylcypromine, thioperamide, and voriconazole represent the first structural characteriza

215 The intravenous use of voriconazole requires coadministration with sulphobutyle

216 is inadequate in detecting the emergence of voriconazole resistance among most Candida species encou

217 Voriconazole resistance was 3% overall but was 8% among

218 I results for fluconazole, posaconazole, and voriconazole, respectively, for each species: 98.9%, 93.

219 or less than the ECV]) for posaconazole and voriconazole, respectively, were as follows: 0.06 (98.5)

220 s mug/ml) for fluconazole, posaconazole, and voriconazole, respectively, were as follows: 0.12, 0.06,

221 isolates for itraconazole, posaconazole, and voriconazole, respectively, were as follows: A. fumigatu

222 The modal MICs (mug/ml) for posaconazole and voriconazole, respectively, were as follows: for C. albi

223 t 180 days were similar with fluconazole and voriconazole, respectively.

224 Discontinuation or dose reduction of voriconazole resulted in improvement of pain in 89% of p

225 Voriconazole route of administration and baseline renal

226 Topical voriconazole seems to be a useful adjunct to natamycin i

227 The CBPs for voriconazole should be reassessed, with consideration fo

228 Discontinuation of voriconazole should be strongly considered in patients e

229 Voriconazole should not be used as monotherapy in filame

230 The trifluorinated molecular structure of voriconazole suggests a possible link between excess flu

231 albicans and C glabrata was observed in all voriconazole-supplemented vials.

232 a rapid and easy method for fluconazole and voriconazole susceptibility testing for timely tailoring

233 od M27-A3 for fluconazole, posaconazole, and voriconazole susceptibility testing of 1,056 isolates of

234 were comparable to those of posaconazole and voriconazole; the MIC90 values for isavuconazole, posaco

235 acute phototoxicity during the first year of voriconazole therapy (mean time, 6 months [range, 0-18 m

236 were randomized to receive either topical 1% voriconazole therapy (n = 20) or intrastromal injections

237 All were started on voriconazole therapy alone.

238 Cumulative mean duration of voriconazole therapy at SCC diagnosis was 35 months (ran

239 as conducted among 195 patients who received voriconazole therapy at St Joseph Mercy Hospital during

240 were common adverse effects associated with voriconazole therapy during the multistate fungal outbre

241 tal pain among patients who are on long-term voriconazole therapy is highly suggestive of periostitis

242 itis, is a reported side effect of long-term voriconazole therapy.

243 tients have improved on receipt of empirical voriconazole therapy.

244 ole concentration for 26 patients undergoing voriconazole therapy.

245 o achieve a prompt diagnosis and to initiate voriconazole therapy.

246 omparative Aspergillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for th

247 dy evaluated the independent contribution of voriconazole to the development of squamous cell carcino

248 here appears to be no benefit to adding oral voriconazole to topical antifungal agents in the treatme

249 atitis may benefit from the addition of oral voriconazole to topical natamycin, and physicians should

250 n EUCAST and CLSI results ranged from 96.9% (voriconazole) to 98.6% (fluconazole).

251 sults ranged from 97.1% (C. parapsilosis and voriconazole) to 99.8% (C. krusei and voriconazole), wit

252 eased rate of perforation or TPK in the oral voriconazole-treated arm; however, this was not a statis

253 best spectacle-corrected visual acuity than voriconazole-treated cases (regression coefficient=0.18

254 Among voriconazole-treated cases, the voriconazole MIC did not

255 .4 points (95% CI, 1.9-14.9) higher than the voriconazole-treated group (P = .01).

256 1-8.5) higher than study participants in the voriconazole-treated group (P = .046).

257 istant A. fumigatus that was associated with voriconazole treatment failure in patients with invasive

258 belief for natamycin treatment compared with voriconazole treatment for filamentous cases as a group

259 r clinical and microbiological outcomes than voriconazole treatment for smear-positive filamentous fu

260 Of the 119 patients (49.6%) in the oral voriconazole treatment group, 65 were male (54.6%), and

261 levels, and was reversible on termination of voriconazole treatment.

262 ths were treated for 3 months with 200 mg of voriconazole twice daily, followed by observation for 9

263 Benefits of voriconazole use when prescribed to lung transplant reci

264 nths, and complication rates associated with voriconazole use.

265 decision support for setting breakpoints for voriconazole using Clinical Laboratory Standards Institu

266 fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods.

267 strains of Candida against posaconazole and voriconazole, using the CLSI M27-A3 broth microdilution

268 activity of PHMB, amphotericin B (AMB), and voriconazole (VCZ) against Aspergillus keratitis.

269 Susceptibility against amphotericin B (AmB), voriconazole (VCZ), and natamycin (NAT) was determined u

270 After shifting the medical regimen to voriconazole via topical and systemic routes (1mg/ml and

271 itraconazole (ITC), posaconazole (POS), and voriconazole (VOR), was examined against seven Candida a

272 lytic than the FDA-approved antifungal agent voriconazole (VOR).

273 Recommended oral voriconazole (VRC) doses are lower than intravenous dose

274 , fluconazole (FLC), posaconazole (PSC), and voriconazole (VRC) for six rarer Candida species (819 st

275 es were obtained in possible IA treated with voriconazole vs AmB with the same magnitude of differenc

276 participants were randomized to receive oral voriconazole vs oral placebo; a voriconazole loading dos

277 .3) or worse were randomized to receive oral voriconazole vs oral placebo; all participants received

278 or the need for TPK was determined for oral voriconazole vs placebo (hazard ratio, 0.82; 95% CI, 0.5

279 400 or worse were randomized to receive oral voriconazole vs placebo.

280 .32 mm; P = .001) in eyes randomized to oral voriconazole vs placebo.

281 Voriconazole was 1 of 2 antifungal agents recommended fo

282 Fungal minimum inhibitory concentration for voriconazole was 4 microg/mL or greater for six of eight

283 Voriconazole was active against all Candida spp. except

284 as cross-resistance between itraconazole and voriconazole was apparent in only 7% of the isolates.

285 Exposure to voriconazole was associated with increased risk of SCC o

286 between 2002 and 2012 in patients treated by voriconazole was launched in France.

287 decreased the activity of antifungal agents; voriconazole was the most affected drugs followed by amp

288 Voriconazole was used to treat 61 patients (92%); 35 pat

289 ng hair loss among our patients treated with voriconazole, we sought to determine the prevalence and

290 EAs for amphotericin B and voriconazole were >90% for most potentially susceptible

291 ole levels varied, and CSF concentrations of voriconazole were approximately 50% those of serum.

292 Susceptibility testing to natamycin and voriconazole were performed according to Clinical and La

293 on and determination of MIC to natamycin and voriconazole were performed according to Clinical and La

294 MICs to natamycin and voriconazole were significantly different across all gen

295 lysis suggests that natamycin is superior to voriconazole when filamentous cases are analyzed as a gr

296 und improvement with natamycin compared with voriconazole, whereas there was almost no difference bet

297 Objective: To compare oral voriconazole with placebo in addition to topical antifun

298 is and voriconazole) to 99.8% (C. krusei and voriconazole), with 0.0 to 2.9% very major discrepancies

299 avuconazole was well tolerated compared with voriconazole, with fewer study-drug-related adverse even

300 atients were treated with antifungal agents (voriconazole, with or without liposomal amphotericin B),